A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon

Journal of Experimental Medicine

Volumn 184, Issue 1, 1996, Pages 165-171

  Welborn III, M Burress ^a   Van Zee, Kimberly ^d,e   Edwards, Paul D ^a   Pruitt, Jeffrey H ^a   Kaibara, Atsushi ^a   Vauthey, J N ^a   Rogy, Michael ^a   Castleman, William L ^b   Lowry, Stephen F ^e   Kenney, John S ^f   Stüber, Dietrich ^c   Ettlin, Urs ^c   Wipf, Beat ^c   Loetscher, Hansruedi ^c   Copeland III, Edward M ^a   Lesslauer, Werner ^c   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b F Hoffmann La Roche Ltd ^*  (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN P55; PROTEIN P75; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR P 75; TUMOR NECROSIS FACTOR RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; CELL PROLIFERATION; CONTROLLED STUDY; HYPOTENSION; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SHOCK; SKIN NECROSIS; T LYMPHOCYTE ACTIVATION; TOXICITY TESTING;

ANIMALS; ANTIGENS, CD; BINDING, COMPETITIVE; BODY TEMPERATURE REGULATION; CYTOKINES; HEMODYNAMIC PROCESSES; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; PAPIO; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SHOCK, SEPTIC; SPECIES SPECIFICITY; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8944220717     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.184.1.165     Document Type: Article

References (25)

1. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411-452.
2. Heller, R.A., K. Song, N. Fan, and D.J. Chang. 1992. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell. 70:47-56.
3. Van Zee, K.J., S.A. Stackpole, W.J. Montegut, M.A. Rogy, S.E. Calvano, K.C. Hsu, M. Chao, C.L. Meschter, H. Loetscher, D. Stüber, et al. 1994. A human tumor necrosis factor (TNF) α mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J. Exp. Med. 179: 1185-1191.
4. Mackay, F., H. Loetscher, D. Stueber, G. Gehr, and W. Lesslauer. 1993. Tumor necrosis factor a (TNF-α)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J. Exp. Med. 177: 1277-1286.
5. Dembic, Z., H. Loetscher, U. Gubler, Y.E. Pan, H. Lahm, R. Gentz, M. Brockhaus, and W. Lesslauer. 1990. Two human TNF receptors have similar extracellular but distinct intracellular, domain sequences. Cytokine. 2:231-237.
6. Menegazzi, R., R. Cramer, P. Patriarca, P. Scheurich, and P. Dri. 1994. Evidence that tumor necrosis factor α (TNF)-induced activation of neutrophil respiratory burst on biologic surfaces is mediated by the p55 TNF receptor. Blood. 84: 287-293.
7. Slowik, M.R., L.G. De Luca, W. Fiers, and J.S. Pober. 1993. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am. J. Pathol. 143:1724-1730.
8. Grell, M., P. Scheurich, A. Meager, and K. Pfizenmaier. 1993. TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lymphokine Cytokine. Res. 12:143-148.
9. Tartaglia, L.A., R.F. Weber, I.S. Figari, C. Reynolds, M.A. Palladino, Jr., and D.V. Goeddel. 1991. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA. 88:9292-9296.
10. Iwamoto, S., I. Shibuya, K. Takeda, and M. Takeda. 1994. Lymphotoxin lacks effects on 75-kDa receptors in cytotoxicity on U-937 cells. Biochem. Biophys. Res. Commun. 199:70-77.
11. Pfeffer, K., T. Matsuyama, T.M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P.S. Ohashi, M. Kronke, and T.W. Mak. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endocoxic shock, yet succumb to L. monocytogenes infection. Cell. 73: 457-467.
12. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature (Lond.). 364:798-802.
13. Gehr, G., R. Gentz, M. Brockhaus, H. Loetscher, and W. Lesslauer. 1992. Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. J. Immunol. 149:911-917.
14. Tartaglia, L.A., D.V. Goeddel, C. Reynolds, I.S. Figari, R.F. Weber, B.M. Fendly, and M.A. Palladino. 1993. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J. Immunol., 151:4637-4641.
15. Cairns, J.A., G.R. Guy, and Y.H. Tan. 1992. Interleukin-6 regulates the cytotoxic effect of tumour necrosis factor on U937 cells. Immunology. 75:669-673.
16. Sheehan, K.C., J.K. Pinckard, C.D. Arthur, L.P. Dehner, D.V. Goeddel, and R.D. Schreiber. 1995. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J. Exp. Med. 181:607-617.
17. Erickson, S.L., F.J. de Sauvage, K. Kikly, K. Carver Moore, S. Pitts Meek, N. Gillett, K.C. Sheehan, R.D. Schreiber, D.V. Goeddel, and M.W. Moore. 1994. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature(Lond.) 372:560-563.
18. Loetscher, H., D. Stueber, D. Banner, F. Mackay, and W. Lesslauer. 1993. Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors J. Biol. Chem. 268:26350-26357.
19. Van Zee, K.J., T. Kohno, E. Fischer, C.S. Rock, L.L. Moldawer, and S.F. Lowry. 1992. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 89: 4845-4849.
20. Sidhu, R.S., and A.P. Bollon. 1993. Tumor necrosis factor activities and cancer-therapy - a perspective. Pharmacol. Ther. 57:79-128.
21. Hieber, U., and M.E. Heim. 1994. Tumor necrosis factor for the treatment of malignancies. Oncology. 51:142-153.
22. Lejeune, F.J., D. Lienard, S. Leyvraz, and R.O. Mirimanoff. 1993. Regional therapy of melanoma. Eur. J. Cancer. 29A: 606-612.
23. Averbook, B.J., R.S. Yamamoto, T.R. Ulich, E.W. Jeffes, I. Masunaka, and G.A. Granger. 1987. Purified native and recombinant human alpha lymphotoxin [tumor necrosis factor (TNF)-beta] induces inflammatory reactions in normal skin. J. Clin. Immunol. 7:333-340.
24. Rampart, M., W. De Smet, W. Fiers, and A.G. Herman. 1989. Inflammatory properties of recombinant tumor necrosis factor in rabbit skin in vivo. J. Exp. Med. 169:2227-2232.
25. Dunn, C.J., M.M. Hardee, and N.D. Staite. 1989. Acute and chronic inflammatory responses to local administration of recombinant IL-1 alpha, IL-beta, TNF alpha, IL-2 and IFN gamma in mice. Agents Actions. 27:290-293.